Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib in metastatic TNBC
NCT04123704Phase 2Terminated
- Sponsor
- Xiang Zhang
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitravatinib in triple-negative breast cancer (TNBC), sponsored by Xiang Zhang. Started Sep 2021; status: terminated.
02
Drugs
sitravatinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04123704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123704.